Progression of immunotherapy in gastric cancer.
- Author:
Xiaoli WEI
;
Ruihua XU
1
Author Information
1. Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China. xurh@sysucc.org.cn.
- Publication Type:Journal Article
- MeSH:
Antibodies, Monoclonal;
therapeutic use;
Antibodies, Monoclonal, Humanized;
therapeutic use;
B7-H1 Antigen;
metabolism;
CTLA-4 Antigen;
metabolism;
Disease Progression;
Humans;
Immunotherapy;
Ipilimumab;
Programmed Cell Death 1 Receptor;
metabolism;
Stomach Neoplasms;
therapy
- From:
Chinese Journal of Gastrointestinal Surgery
2016;19(2):225-232
- CountryChina
- Language:Chinese
-
Abstract:
Gastric cancer is a malignant disease with high incidence and mortality. The therapeutic methods for advanced gastric cancer, including chemotherapy and targeted therapy are very limited. Immunotherapy is a new method for cancer treatment. The immune checkpoint inhibitors developed for cancer treatment mainly target the CTLA-4 and PD-1/PD-L pathways. There have already been several inhibitors approved for the treatment of melanoma and non-small cell lung cancer by the FDA, including Ipilimumab (fully human antibody against CTLA-4), Pembrolizumab (fully human antibody against PD-1) and Nivolumab (fully human antibody against PD-1). There are also many on-going clinical trials investigating the value of immune checkpoint inhibitors in treating various malignancies, including advanced gastric cancer. In KEYNOTE-012 trial, for advanced gastric and esophagogastric junction cancer anti-PD-1 therapy seemed to be safe and effective for advanced gastric cancer with PD-L1 positivity. Moreover, studies of adoptive cell therapy and tumor vaccine in gastric cancer are underway. Here the latest developments in immunotherapy for gastric cancer will be illustrated.
